The dramatic finding that an antibody that inhibits interleukin-1b (IL-1b) can reduce the risk of heart attack and stroke is the first clinical evidence that tackling the inflammatory component of cardiovascular disease can benefit patients.

Click here  to original publication.

Fonte: NATURE BIOTECHNOLOGY VOLUME 35 NUMBER 10 OCTOBER 2017 893